Fosamax (Alendronate) for Glucocorticoid-Induced Osteoporosis: What Women Need to Know

Is Fosamax approved for glucocorticoid-induced osteoporosis?

Alendronate is not FDA-approved for glucocorticoid-induced osteoporosis (GIOP) as a standalone, named indication. Its FDA-approved indications cover postmenopausal osteoporosis (treatment and prevention), osteoporosis in men, and Paget's disease of bone. Use for GIOP is considered off-label, meaning clinicians prescribe it based on published clinical evidence and guideline recommendations rather than a specific FDA-approved label for that condition.

That distinction matters for insurance coverage and for the conversations you should have with your prescriber. It does not mean the use is fringe or unproven.

Why off-label does not mean unproven

The American College of Rheumatology (ACR) 2022 guideline on the prevention and treatment of GIOP conditionally recommends oral bisphosphonates, including alendronate, as first-line agents for adults at moderate-to-high fracture risk who are starting or currently taking glucocorticoids at a dose of 2.5 mg prednisone-equivalent or more per day for three months or longer. This guideline assigns a GRADE of conditional recommendation, moderate-quality evidence to alendronate for this use.

The 1998 randomized controlled trial by Saag et al., published in the New England Journal of Medicine, enrolled 477 women and men already on glucocorticoids and demonstrated that alendronate 5 mg or 10 mg daily significantly increased lumbar spine bone mineral density (BMD) compared with placebo over 48 weeks. Lumbar spine BMD rose by approximately 2.1% with alendronate 10 mg daily versus a loss of 0.4% in the placebo group. That trial is the cornerstone of the off-label evidence base.

The risedronate comparison

Risedronate (Actonel) does carry an FDA-approved indication specifically for GIOP, which sometimes prompts prescribers to reach for it first. Alendronate and risedronate have not been compared head-to-head in a large powered GIOP trial, so the choice between them rests on access, tolerability, and individual clinical factors rather than on proven superiority of one agent. Your prescriber will weigh cost and your GI history.

How glucocorticoids damage bone, and why women are more vulnerable

Corticosteroids disrupt bone remodeling through several direct mechanisms: they suppress osteoblast activity, increase osteoclast lifespan, impair intestinal calcium absorption, and raise urinary calcium excretion. The result is net bone loss that is fastest in the first three to six months of therapy, when spinal trabecular bone can fall by up to 12% in the first year of high-dose treatment.

Women carry an additional layer of vulnerability at every life stage.

Reproductive years

During the reproductive years, estrogen partly offsets osteoclast activity. A woman who develops a condition requiring long-term steroids (lupus, inflammatory bowel disease, severe asthma, rheumatoid arthritis) while she is still cycling may lose that partial protection if the underlying disease or the steroids suppress her hypothalamic-pituitary-ovarian axis, suppressing estrogen. Amenorrhea linked to chronic illness or steroid use accelerates bone loss beyond what the steroids alone would cause.

Perimenopause

Perimenopause is the worst possible time to start long-term glucocorticoids. Estrogen levels are already declining erratically, trabecular bone in the spine is already at peak vulnerability, and adding a potent bone-resorption stimulus can collapse years of bone accrual in months. A perimenopausal woman starting prednisone 7.5 mg or more daily should have a DXA scan within the first month of therapy and a direct conversation about both bisphosphonate therapy and whether menopausal hormone therapy is appropriate.

Post-menopause

Post-menopausal women lose the estrogen buffer entirely. The ACR 2022 GIOP guideline flags this group as consistently high-risk: even a prednisone dose as low as 2.5 mg per day for three months or more qualifies many post-menopausal women for pharmacologic treatment rather than just calcium and vitamin D supplementation.

Off-label dosing: what is actually used in practice

For GIOP, the alendronate doses studied in the Saag trial were 5 mg and 10 mg daily. In current clinical practice, most prescribers use the once-weekly 70 mg tablet, which is bioequivalent to 10 mg daily and dramatically improves adherence. The ACR 2022 guideline does not specify daily versus weekly dosing, leaving that to prescriber and patient preference; real-world adherence data consistently favor the weekly formulation.

The 70 mg weekly tablet must be taken:

• On an empty stomach, first thing in the morning
• With a full glass of plain water (at least 6 to 8 ounces)
• At least 30 minutes before any food, drink, or other medication
• While remaining upright (sitting or standing) for at least 30 minutes after swallowing

These instructions are not optional. Alendronate's oral bioavailability is approximately 0.6% under fasting conditions and drops further if taken with food or coffee. Esophageal injury, including esophageal ulceration, has been reported when tablets are taken incorrectly or when the patient lies down afterward.

Dose adjustments by renal function

Alendronate is renally cleared. It is not recommended when creatinine clearance is below 35 mL/min. Women with lupus nephritis, diabetic kidney disease, or other conditions that commonly coexist with long-term steroid use need renal function checked before starting alendronate and monitored during therapy.

Pregnancy, lactation, and contraception: a required read before you start

Alendronate is contraindicated in pregnancy. Animal reproduction studies showed fetal harm at doses producing maternal plasma levels similar to those achieved with the clinical dose. FDA pregnancy category guidance classifies alendronate as category C (harm in animal studies, no adequate human trials), and the current prescribing information states it should not be used during pregnancy.

The additional concern specific to bisphosphonates is their very long skeletal half-life, estimated at more than 10 years for alendronate. Drug incorporated into your bone matrix continues to release slowly into the bloodstream long after you stop taking it. Case reports of bisphosphonate exposure during pregnancy have not shown consistent fetal harm in humans, but the data are sparse and reassurance cannot be offered confidently. The ACOG Practice Bulletin framework on osteoporosis advises deferring bisphosphonate therapy in women who are pregnant or planning pregnancy in the near term.

What this means for reproductive-age women

If you are a woman of reproductive potential (any woman who has not reached confirmed menopause) starting alendronate for GIOP, you need reliable contraception for the duration of therapy. Your prescriber should discuss how long you plan to use the drug and whether you want biological children, because the skeletal accumulation means fracture risk and fetal exposure must both be planned around years in advance, not just while you are actively taking the pill.

Lactation

Data on alendronate transfer into breast milk are extremely limited. Animal studies suggest low transfer, but no adequate human lactation pharmacokinetic studies exist. Given the lack of safety data and the availability of alternative approaches for postpartum bone management, most clinicians advise against alendronate during breastfeeding.

GIOP in pregnancy itself

Glucocorticoid use in pregnancy is sometimes medically necessary (for example, severe lupus flares or preterm birth prevention). Pregnancy-associated osteoporosis is a distinct and underdiagnosed condition. Alendronate is not used to treat it. Calcium, vitamin D, and load-bearing activity are the interventions used during pregnancy, with specialist review of the underlying inflammatory disease.

Monitoring requirements: what labs and scans you actually need

Monitoring for GIOP on alendronate is not optional. It is the mechanism by which your clinician confirms you are responding, catches side effects early, and decides how long to continue therapy.

Before you start

Your clinician should order:

• DXA scan of the lumbar spine and hip to establish your baseline T-score and identify prevalent vertebral fractures
• Serum calcium and albumin to rule out hypocalcemia, which is a contraindication to starting bisphosphonate therapy
• 25-hydroxyvitamin D because vitamin D deficiency must be corrected before starting alendronate (target is typically 30 ng/mL or above before initiation)
• Serum creatinine and estimated GFR to confirm renal function is adequate
• FRAX score calculation to quantify 10-year fracture risk and confirm treatment threshold is met; the ACR 2022 guideline incorporates FRAX with the glucocorticoid dose adjustment

During therapy

The ACR guideline and standard practice support:

• DXA every one to two years while on glucocorticoids, with intervals shortening to one year in women who are perimenopausal, post-menopausal, or on high-dose steroids (prednisone equivalent at or above 7.5 mg daily)
• Serum calcium and 25-OH vitamin D at least annually, more often if you have GI malabsorption or are on high-dose vitamin D supplementation
• Renal function at least annually
• Bone turnover markers (serum CTX or P1NP) are optional but may help assess adherence and response between DXA intervals; a rising CTX on treatment suggests either poor adherence or, rarely, an alternative diagnosis

The atypical femur fracture signal

Atypical subtrochanteric and diaphyseal femur fractures are a rare but recognized complication of long-term bisphosphonate use, with risk rising after three to five years of continuous therapy. FDA safety communications note that the absolute risk is low but real. Women taking alendronate for GIOP should report new thigh or groin pain promptly; imaging should be obtained to rule out an evolving atypical fracture or a stress reaction.

Women on glucocorticoids who are also taking high-dose corticosteroids for rheumatologic conditions may receive concomitant medications (methotrexate, hydroxychloroquine, other DMARDs) that require their own monitoring. Coordinate with your rheumatologist or internist to consolidate lab draws when possible.

Who this is right for (and who it is not)

Women most likely to benefit

• Post-menopausal women on any dose of prednisone equivalent for three months or more who have a T-score at or below negative 2.5, or who have had a fracture
• Perimenopausal women on prednisone 7.5 mg or more daily with a T-score between negative 1.0 and negative 2.5
• Reproductive-age women with a T-score at or below negative 2.5 who are on chronic high-dose steroids and are using reliable contraception
• Women at moderate-to-high FRAX-calculated fracture risk using the glucocorticoid adjustment, regardless of DXA T-score alone

Women for whom alendronate is not appropriate

• Pregnant women or those planning pregnancy without a structured conversation about timing and alternatives first
• Women with creatinine clearance below 35 mL/min
• Women with active upper GI disease (esophageal stricture, achalasia, active esophagitis) because the esophageal irritation risk is unacceptable
• Women who cannot maintain an upright posture for 30 minutes after taking the tablet
• Women with uncorrected hypocalcemia

Alternatives when alendronate is not the right fit

Risedronate is the only bisphosphonate with a dedicated FDA-approved GIOP indication and may be preferred when insurance coverage is a barrier to off-label alendronate. Zoledronic acid (IV, once yearly) is an option for women with GI intolerance to oral bisphosphonates. Denosumab and teriparatide are used for severe GIOP, particularly in post-menopausal women with very low BMD or multiple fractures, though each carries its own safety and monitoring profile. The ACR 2022 guideline positions teriparatide as preferred over oral bisphosphonates in very high-risk patients.

Female-specific conditions that change the clinical picture

PCOS

Women with PCOS who are treated with oral corticosteroids (historically used in some protocols to suppress adrenal androgen production) are a small but real group who may encounter GIOP risk. Metformin, sometimes used in PCOS, does not directly affect fracture risk but does not substitute for bisphosphonate therapy when GIOP thresholds are met.

Lupus

Lupus disproportionately affects women and is one of the most common conditions driving long-term steroid use. Lupus itself is independently associated with lower BMD and higher fracture risk through disease-related inflammation, renal involvement, and reduced physical activity. Every woman with lupus on chronic steroids should have GIOP assessment at the time steroids are initiated.

Inflammatory bowel disease

IBD affects calcium absorption directly. Women with Crohn's disease or ulcerative colitis on corticosteroids carry a double hit to bone: malabsorption reduces calcium and vitamin D uptake, and the steroids suppress osteoblasts. Vitamin D deficiency must be actively corrected before alendronate is started, and higher replacement doses may be needed compared with the general population.

Rheumatoid arthritis

RA itself drives inflammatory bone loss through RANKL upregulation. Women with RA on low-dose prednisone (2.5 to 5 mg daily) for years accumulate fracture risk steadily. The ACR 2022 guideline was written with this population centrally in mind.

Evidence gaps: what we do not know yet

Women have been underrepresented in many foundational bisphosphonate trials, and GIOP research is no exception. The Saag 1998 trial enrolled approximately 55% women, but the analysis was not powered to examine sex-specific outcomes separately. We do not have a clear answer on whether alendronate's BMD effect in premenopausal women with GIOP translates to the same fracture risk reduction as it does in post-menopausal women, because fracture as an outcome requires very large sample sizes that GIOP trials have not achieved.

The ACR guideline acknowledges this gap: conditional recommendations for premenopausal women rest partly on extrapolation from post-menopausal data. Asking your prescriber to name the specific evidence tier behind your treatment plan is a legitimate question, not a challenge.

How long to continue alendronate for GIOP

The optimal duration of alendronate for GIOP has not been established by a dedicated long-term trial. For postmenopausal osteoporosis, many guidelines suggest reassessing after three to five years with a "drug holiday" for lower-risk women, but GIOP creates an ongoing stimulus for bone loss as long as steroids continue. Most clinicians continue alendronate for the duration of glucocorticoid therapy at doses that triggered treatment, then reassess with DXA and fracture risk recalculation when steroids are tapered or stopped.

A woman who discontinues both steroids and alendronate should have a follow-up DXA at one to two years post-discontinuation to confirm that BMD is stable or recovering rather than continuing to decline.

The ACR 2022 guideline states clearly that in high-risk patients, the threshold to continue treatment should be reviewed at least every one to two years.